Bronze level automatically awarded GB final

This data has achieved Bronze level on 29 October 2014 which means this data makes a great start at the basics of publishing open data.

Use of NICE appraised medicines in the NHS in England – 2010 and 2011, experimental statistics

Summary

Type of release
a one-off release of a single dataset

Licence
UK Open Government Licence

Verification
automatically awarded

Release Date
28 November 2012
Modified Date
12 August 2013
Publishers
Health and Social Care Information Centre
Keywords
Health

Community verification

Other people can verify whether the answers on this certificate are correct.

This certificate is automatically awarded.

Sign in to verify or report this certificate


Description

The National Institute for Health and Clinical Excellence (NICE) technology appraisal process assesses the clinical and cost effectiveness of new and existing drugs and treatments, and provides guidance on their use by the NHS. As part of the Pharmaceutical Price Regulation Scheme (PPRS) agreement which came into operation on 1 January 2009, the Department of Health (DH) and the Association of the British Pharmaceutical Industry agreed that the DH would review the variation in uptake of selected medicines in the NHS in England. The NHS Information Centre was asked to produce a bulletin looking at variation in the use of these medicines in relation to the number of eligible patients as estimated by NICE. Data on the number of patients being treated is not available and so predicted use (using the average dose and average length of treatment) was compared with observed use. Data on observed use in 2010 and 2011 was taken from the primary care prescribing data from NHS Prescribing Services and secondary care data provided by IMS Health. Several pharmaceutical companies also provided their own data. In all 52 medicines in 25 groups, relating to 35 technology appraisals, were considered. For 13 groups a comparison could be made (these are presented in Section 1 of the technology section results). For those appraisals where a valid comparison could not be made (these are presented in Section 2 of the technology results), the reasons why the comparison could not be made are presented along with a series of questions inviting the reader to suggest improvements to the method or data. A third section presents an approach to analysing the use of biologics medicines for the treatment of rheumatoid arthritis on which we welcome comments.


General Information


Legal Information

  • This data was

    originally created or generated by its curator Do you think this data is incorrect? Let us know

  • The rights statement is at

    http://data.gov.uk/dataset/use-of-nice-appraised-medicines-in-the-nhs-in-england-2010-and-2011-experimental-statistics Do you think this data is incorrect? Let us know

  • This data is available under

    UK Open Government Licence Do you think this data is incorrect? Let us know

  • There are

    yes, and the rights are all held by the same person or organisation Do you think this data is incorrect? Let us know

  • The content is available under

    UK Open Government Licence Do you think this data is incorrect? Let us know

  • This data contains

    no data about individuals Do you think this data is incorrect? Let us know


Practical Information

  • The data appears in this collection

    http://data.gov.uk Do you think this data is incorrect? Let us know


Technical Information

  • The format of this data is

    a standard open format Do you think this data is incorrect? Let us know


Social Information

  • The documentation includes machine-readable data for

    title Do you think this data is incorrect? Let us know

  • The documentation includes machine-readable data for

    description Do you think this data is incorrect? Let us know

  • The documentation includes machine-readable data for

    publisher Do you think this data is incorrect? Let us know

  • The documentation includes machine-readable data for

    keyword(s) or tag(s) Do you think this data is incorrect? Let us know

  • The documentation includes machine-readable data for

    distribution(s) Do you think this data is incorrect? Let us know

  • The documentation includes machine-readable data for

    release date Do you think this data is incorrect? Let us know

  • The documentation includes machine-readable data for

    modification date Do you think this data is incorrect? Let us know